Company Overview and News

10
PAM / Pampa Energia S.A. PAM20180914_6K (Current Report of Foreign Issuer)

2018-09-14 sec.gov
pam20180914_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PAM

10
PAM / Pampa Energia S.A. / Pampa Energy Inc. - SCHEDULE 13D/A (Activist Investment)

2018-09-07 sec.gov
pam20180905_sc13da.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PAM

10
PAM / Pampa Energia S.A. FORM 6-K/A (Current Report of Foreign Issuer)

2018-09-06 sec.gov
pam20180906_6ka.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PAM

10
PAM / Pampa Energia S.A. PAM20180904_6K (Current Report of Foreign Issuer)

2018-09-04 sec.gov
pam20180904_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PAM

11
PAM / Pampa Energia S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-09-04 sec.gov - 1
pam20180903_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PAM

12
PAM / Pampa Energia S.A. PAM20180830_6K (Current Report of Foreign Issuer)

2018-08-30 sec.gov - 2
pam20180830_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
PAM

10
PAM / Pampa Energia S.A. PAM20180829_6K (Current Report of Foreign Issuer)

2018-08-29 sec.gov
pam20180829_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
PAM

10
PAM / Pampa Energia S.A. PAM20180829_6K1 (Current Report of Foreign Issuer)

2018-08-29 sec.gov
pam20180829_6k1.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K &nbs
PAM

10
PAM / Pampa Energia S.A. PAM20180828_6K (Current Report of Foreign Issuer)

2018-08-28 sec.gov
pam20180828_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
PAM

10
PAM / Pampa Energia S.A. PAM20180827_6K (Current Report of Foreign Issuer)

2018-08-27 sec.gov
pam20180827_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
PAM

10
PAM / Pampa Energia S.A. 6-K (Current Report of Foreign Issuer)

2018-08-24 sec.gov
pam20180824_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
PAM

10
PAM / Pampa Energia S.A. PAM20180823_6K (Current Report of Foreign Issuer)

2018-08-23 sec.gov
pam20180823_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
PAM

10
PAM / Pampa Energia S.A. 6-K (Current Report of Foreign Issuer)

2018-08-22 sec.gov
pam20180822_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
PAM

10
PAM / Pampa Energia S.A. PAMFS2Q18_6K (Current Report of Foreign Issuer)

2018-08-22 sec.gov
pamfs2q18_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
PAM

10
PAM / Pampa Energia S.A. PAM20180821_6K (Current Report of Foreign Issuer)

2018-08-21 sec.gov
pam20180821_6k.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K
PAM

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to PAM / Pampa Energia S.A. on message board site Silicon Investor.

SI Spammer Hall of Fame SI Spammer Hall of Fame SI Spammer Hall of Fame (PAMT) Is it really the sweet sound of music or a fleecing t (PAMT) Is it really the sweet sound of music or a fleecing t (PAMT) Is it really the sweet sound of music or a fleecing t
spam test only spam test only spam test only Show us your spam! Show us your spam! Show us your spam!
SPAMMING DONKEYS is still SPAMMING... SPAMMING DONKEYS is still SPAMMING... SPAMMING DONKEYS is still SPAMMING... PBCI: Pamrapo Bancorp, Inc. PBCI: Pamrapo Bancorp, Inc. PBCI: Pamrapo Bancorp, Inc.
Comtouch SPAM Solutions (E-Mail) (NASDAQ:CTCH) Comtouch SPAM Solutions (E-Mail) (NASDAQ:CTCH) Comtouch SPAM Solutions (E-Mail) (NASDAQ:CTCH) Spammed Stock Bit Bucket Spammed Stock Bit Bucket Spammed Stock Bit Bucket
Qcom-oldtimers and veterans without spam board Qcom-oldtimers and veterans without spam board Qcom-oldtimers and veterans without spam board Zeevu0027s Turnips- No Spammers Zeevu0027s Turnips- No Spammers Zeevu0027s Turnips- No Spammers
CUSIP: 697660207